Literature DB >> 21673011

Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Xianmin Luo1, Megan K Ruhland, Ermira Pazolli, Anne C Lind, Sheila A Stewart.   

Abstract

Alterations in the microenvironment collaborate with cell autonomous mutations during the transformation process. Indeed, cancer-associated fibroblasts and senescent fibroblasts stimulate tumorigenesis in xenograft models. Because senescent fibroblasts accumulate with age, these findings suggest that they contribute to age-related increases in tumorigenesis. Previously we showed that senescence-associated stromal-derived osteopontin contributes to preneoplastic cell growth in vitro and in xenografts, suggesting that it impacts neoplastic progression. Analysis of fibroblasts within premalignant and malignant skin lesions ranging from solar/actinic keratosis to squamous cell carcinoma revealed they express osteopontin. Given the stromal expression of osteopontin, we investigated how osteopontin impacts preneoplastic cell growth. We show that osteopontin promotes preneoplastic keratinocyte cellular proliferation and cell survival through the CD44 cell receptor and activation of the MAPK pathway. These data suggest that stromal-derived osteopontin impacts tumorigenesis by stimulating preneoplastic cell proliferation thus allowing expansion of initiated cells in early lesions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21673011      PMCID: PMC3685505          DOI: 10.1158/1541-7786.MCR-10-0472

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  79 in total

1.  CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis.

Authors:  Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

Review 2.  Osteopontin function in pathology: lessons from osteopontin-deficient mice.

Authors:  S R Rittling; D T Denhardt
Journal:  Exp Nephrol       Date:  1999 Mar-Apr

3.  Prediction and validation of the distinct dynamics of transient and sustained ERK activation.

Authors:  Satoru Sasagawa; Yu-ichi Ozaki; Kazuhiro Fujita; Shinya Kuroda
Journal:  Nat Cell Biol       Date:  2005-03-27       Impact factor: 28.824

4.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

5.  Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.

Authors:  Hidemi Teramoto; Maria Domenica Castellone; Renae L Malek; Noah Letwin; Bryan Frank; J Silvio Gutkind; Norman H Lee
Journal:  Oncogene       Date:  2005-01-13       Impact factor: 9.867

6.  Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity.

Authors:  R E Devoll; W Li; K V Woods; G J Pinero; W T Butler; M C Farach-Carson; R P Happonen
Journal:  J Oral Pathol Med       Date:  1999-03       Impact factor: 4.253

Review 7.  Targeting the mitogen-activated protein kinase cascade to treat cancer.

Authors:  Judith S Sebolt-Leopold; Roman Herrera
Journal:  Nat Rev Cancer       Date:  2004-12       Impact factor: 60.716

8.  Tumour biology: senescence in premalignant tumours.

Authors:  Manuel Collado; Jesús Gil; Alejo Efeyan; Carmen Guerra; Alberto J Schuhmacher; Marta Barradas; Alberto Benguría; Angel Zaballos; Juana M Flores; Mariano Barbacid; David Beach; Manuel Serrano
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

9.  Oncogene-induced senescence as an initial barrier in lymphoma development.

Authors:  Melanie Braig; Soyoung Lee; Christoph Loddenkemper; Cornelia Rudolph; Antoine H F M Peters; Brigitte Schlegelberger; Harald Stein; Bernd Dörken; Thomas Jenuwein; Clemens A Schmitt
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

10.  The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation.

Authors:  S J Cook; N Aziz; M McMahon
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

View more
  19 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

Review 2.  Insidious changes in stromal matrix fuel cancer progression.

Authors:  Fayth L Miles; Robert A Sikes
Journal:  Mol Cancer Res       Date:  2014-01-22       Impact factor: 5.852

3.  Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3β and osteopontin.

Authors:  Nabeel Abdulrahman; Maiy Jaballah; Noufira Poomakkoth; Sadaf Riaz; Somaia Abdelaziz; Aya Issa; Fatima Mraiche
Journal:  Mol Cell Biochem       Date:  2016-05-28       Impact factor: 3.396

4.  Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).

Authors:  Kenneth D Rice; Naing Aay; Neel K Anand; Charles M Blazey; Owen J Bowles; Joerg Bussenius; Simona Costanzo; Jeffry K Curtis; Steven C Defina; Larisa Dubenko; Stefan Engst; Anagha A Joshi; Abigail R Kennedy; Angie I Kim; Elena S Koltun; Julie C Lougheed; Jean-Claire L Manalo; Jean-Francois Martini; John M Nuss; Csaba J Peto; Tsze H Tsang; Peiwen Yu; Stuart Johnston
Journal:  ACS Med Chem Lett       Date:  2012-04-09       Impact factor: 4.345

5.  Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development.

Authors:  Pi-Ling Chang; Yu-Hua Hsieh; Chao-Cheng Wang; M Margaret Juliana; Yuko Tsuruta; Laura Timares; Craig Elmets; Kang-Jey Ho
Journal:  J Dermatol Sci       Date:  2014-05-21       Impact factor: 4.563

6.  Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4.

Authors:  Monika Rabenstein; Joerg Hucklenbroich; Antje Willuweit; Anne Ladwig; Gereon Rudolf Fink; Michael Schroeter; Karl-Josef Langen; Maria Adele Rueger
Journal:  Stem Cell Res Ther       Date:  2015-05-22       Impact factor: 6.832

7.  Hydrocellular foam dressing promotes wound healing along with increases in hyaluronan synthase 3 and PPARα gene expression in epidermis.

Authors:  Takumi Yamane; Gojiro Nakagami; Sawako Yoshino; Aimi Muramatsu; Sho Matsui; Yuichi Oishi; Toshiki Kanazawa; Takeo Minematsu; Hiromi Sanada
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

8.  Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours.

Authors:  Laura E Thomas; Jincy Winston; Ellie Rad; Matthew Mort; Kayleigh M Dodd; Andrew R Tee; Fionnuala McDyer; Stephen Moore; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2015-02-15       Impact factor: 4.639

9.  Functional characterization of stromal osteopontin in melanoma progression and metastasis.

Authors:  Santosh Kumar; Priyanka Sharma; Dhiraj Kumar; Goutam Chakraborty; Mahadeo Gorain; Gopal C Kundu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis.

Authors:  Kun Xu; Xuejun Tian; Sun Y Oh; Mohammad Movassaghi; Stephen P Naber; Charlotte Kuperwasser; Rachel J Buchsbaum
Journal:  Breast Cancer Res       Date:  2016-01-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.